BRPI0920251A2 - composto, composição famacêutica, formulação, métodos para preparar o composto, um sal farmaceuticamente aceitável, para inibir o crescimento de um micróbio, para tratar um mamífero tendo uma infecção microbiana, e, uso de um composto. - Google Patents

composto, composição famacêutica, formulação, métodos para preparar o composto, um sal farmaceuticamente aceitável, para inibir o crescimento de um micróbio, para tratar um mamífero tendo uma infecção microbiana, e, uso de um composto.

Info

Publication number
BRPI0920251A2
BRPI0920251A2 BRPI0920251A BRPI0920251A BRPI0920251A2 BR PI0920251 A2 BRPI0920251 A2 BR PI0920251A2 BR PI0920251 A BRPI0920251 A BR PI0920251A BR PI0920251 A BRPI0920251 A BR PI0920251A BR PI0920251 A2 BRPI0920251 A2 BR PI0920251A2
Authority
BR
Brazil
Prior art keywords
compound
microbe
mammal
inhibiting
formulation
Prior art date
Application number
BRPI0920251A
Other languages
English (en)
Portuguese (pt)
Inventor
Bozena Korczak
Dahui Liu
Haizhong Tang
Richard W Scott
William F Degrado
Yongjiang Xu
Original Assignee
Polymedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymedix Inc filed Critical Polymedix Inc
Publication of BRPI0920251A2 publication Critical patent/BRPI0920251A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0920251A 2008-10-27 2009-10-27 composto, composição famacêutica, formulação, métodos para preparar o composto, um sal farmaceuticamente aceitável, para inibir o crescimento de um micróbio, para tratar um mamífero tendo uma infecção microbiana, e, uso de um composto. BRPI0920251A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10859508P 2008-10-27 2008-10-27
US12/605,584 US8278309B2 (en) 2008-10-27 2009-10-26 Synthetic mimetics of host defense and uses thereof
PCT/US2009/062147 WO2010062573A1 (en) 2008-10-27 2009-10-27 Synthetic mimetics of host defense and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0920251A2 true BRPI0920251A2 (pt) 2016-01-05

Family

ID=42118100

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920251A BRPI0920251A2 (pt) 2008-10-27 2009-10-27 composto, composição famacêutica, formulação, métodos para preparar o composto, um sal farmaceuticamente aceitável, para inibir o crescimento de um micróbio, para tratar um mamífero tendo uma infecção microbiana, e, uso de um composto.

Country Status (14)

Country Link
US (2) US8278309B2 (https=)
EP (1) EP2358380A4 (https=)
JP (1) JP2012506908A (https=)
KR (1) KR20110074995A (https=)
CN (1) CN102256614B (https=)
AU (1) AU2009320139B2 (https=)
BR (1) BRPI0920251A2 (https=)
CA (1) CA2741764A1 (https=)
IL (1) IL212275A0 (https=)
MX (1) MX2011004360A (https=)
RU (1) RU2540077C2 (https=)
TW (1) TWI478915B (https=)
UA (1) UA104875C2 (https=)
WO (1) WO2010062573A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092574A1 (en) * 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
TWI478915B (zh) * 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途
EP2709619B1 (en) * 2011-05-16 2017-10-11 Cellceutix Corporation Compounds for use in treatment of mucositis
US9758607B2 (en) 2013-10-10 2017-09-12 Research Foundation Of The City University Of New York Polymer with antibacterial activity
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
CN107574581B (zh) * 2017-08-03 2019-09-10 天津大学 一种抗菌性聚(ε-己内酯)/模拟抗菌肽电纺纤维膜及其制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021248008A1 (en) * 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
DK0629347T3 (da) 1992-01-23 1998-02-16 Morinaga Milk Industry Co Ltd Antibakterielt middel og behandling af genstande dermed
DE69907476T2 (de) 1998-08-20 2004-04-15 The University Of North Carolina At Chapel Hill Office Of Technology Development Dibenzothiophene derivate und ihre verwendung
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
EP3045168A1 (en) 2000-11-08 2016-07-20 FXS Ventures, LLC Improved ophthalmic and contact lens solution
EP2289524A1 (en) 2001-03-08 2011-03-02 The Trustees Of The University Of Pennsylvania Facially amphiphillic polymers as anti-infective agents
WO2003045307A2 (en) 2001-11-21 2003-06-05 Sugen, Inc. Pharmaceutical formulations comprising indolinone derivatives
CA2487454A1 (en) 2002-05-28 2003-12-04 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
EP1513622A4 (en) 2002-06-13 2005-09-14 Univ Pennsylvania METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR STIMULATING BIOMEMBRANES USING ROUGH GRAIN MODELS
EP2471526A3 (en) 2003-03-17 2012-12-12 The Trustees Of The University Of Pennsylvania Facially amphiphillic polymers and oligomers and uses thereof
AU2003249114A1 (en) 2003-03-20 2004-10-11 Shiseido International France Cosmetic composition
US20050065091A1 (en) 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
CN1922133A (zh) 2004-01-23 2007-02-28 宾夕法尼亚州大学理事会 表面两亲性聚芳基和聚芳基炔基聚合物和低聚物及其用途
PL2708225T3 (pl) 2004-04-23 2019-07-31 Cydex Pharmaceuticals, Inc. Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
AU2005254574B2 (en) 2004-06-15 2012-02-02 Polymedix, Inc. Polycationic compounds and uses thereof
JP5027659B2 (ja) 2004-07-23 2012-09-19 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗菌コポリマーおよびその使用
DK2377557T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
US20100048498A1 (en) 2004-12-21 2010-02-25 Johnson Barbara A Stable non-dihydrate azithromycin oral suspensions
US20060241052A1 (en) 2005-02-25 2006-10-26 Degrado William F Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
RU2325151C2 (ru) * 2006-06-29 2008-05-27 ООО "Научно-производственный центр "Амфион" Способ получения системы доставки водонерастворимых и плохорастворимых биологически активных веществ и лекарственная форма на ее основе
JP2008137978A (ja) 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
US20090092574A1 (en) * 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
RU2530899C2 (ru) 2008-07-28 2014-10-20 Селлсьютикс Корпорейшн Противомалярийные соединения
TWI478915B (zh) * 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途

Also Published As

Publication number Publication date
RU2011121354A (ru) 2012-12-10
MX2011004360A (es) 2011-08-12
KR20110074995A (ko) 2011-07-05
UA104875C2 (uk) 2014-03-25
TW201020249A (en) 2010-06-01
CN102256614A (zh) 2011-11-23
RU2540077C2 (ru) 2015-01-27
CN102256614B (zh) 2014-01-08
IL212275A0 (en) 2011-06-30
AU2009320139B2 (en) 2013-07-25
AU2009320139A1 (en) 2010-06-03
CA2741764A1 (en) 2010-06-03
US20100105703A1 (en) 2010-04-29
EP2358380A1 (en) 2011-08-24
US8278309B2 (en) 2012-10-02
EP2358380A4 (en) 2012-05-02
JP2012506908A (ja) 2012-03-22
US8975262B2 (en) 2015-03-10
TWI478915B (zh) 2015-04-01
US20130090345A1 (en) 2013-04-11
WO2010062573A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
BR112012003578A2 (pt) composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal.
BRPI0920251A2 (pt) composto, composição famacêutica, formulação, métodos para preparar o composto, um sal farmaceuticamente aceitável, para inibir o crescimento de um micróbio, para tratar um mamífero tendo uma infecção microbiana, e, uso de um composto.
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0720637A2 (pt) Composto ou um sal farmaceuticamente aceitável, uma forma estereoisomérica, tautomérica ou polimórfica do mesmo, métodos para o tratamento de um hospedeiro e de tratamento de infecção, composição farmacêutica, e, uso do composto
CL2007002188A1 (es) Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal.
BRPI0819799A2 (pt) Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0916235A2 (pt) composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
BRPI0907976A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0920042A2 (pt) uso de um composto, dispositivo médico implantável, método para a sua fabricação, e, método in vitro para exterminar, inibir ou prevenir o crescimento de um biofilme microbiano.
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0820568A2 (pt) Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
BRPI1013394A2 (pt) "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
CL2007002431A1 (es) Compuestos derivados de azabenzotiofenil; composicion farmaceutica; y uso para la inhibicion del crecimiento celular anomalo o de tratamiento de un trastorno hiperproliferativo.
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1007624A2 (pt) composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste
BRPI1013988A2 (pt) composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BR112012003462A2 (pt) "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
CL2007003130A1 (es) Uso de una formulacion de liberacion inmediata con un ingrediente activo seleccionado de pramipexol, hidrocloruro de pramipexol, dihidrocloruro de pramipexol monohidrato o una sal farmaceuticamente aceptable de este, para el tratamiento de la enferme
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
BRPI0914371A2 (pt) "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CELLCEUTIX CORPORATION (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]